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The use of trastuzumab as intact IgG labeling radionuclide for HER2 positive breast cancer
theranostic agent is not ideal because it is slowly eliminated from the blood and normal
tissues resulting in low tumor/blood (T/B) and tumor/normal tissue (T/NT) ratios. To
overcome this limitation, we developed the trastuzumab F(ab0)2 fragments and radio-
labeling of the fragments by b and g-particle of Lutetium-177. F(ab)2 fragments were pro-
duced by digestion of trastuzumab IgG (Herceptin) with pepsin for 18 h at 37 C. The F(ab0)2
fragment fractionated in PD-10 column, followed by the conjugation with 2-(4-
isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (p-SCN-Bn-
DOTA) as a metal chelator and radiolabeling with 177LuCl3. Molecular weight of fragments
was calculated by LCMS (Liquid Chromatography Mass Spectroscopy) and the radio-
chemical purity was evaluated by ITLC-SG (Instan Thin Layer Chromatography). Our study
showed that the purity of F(ab0)2 fragment generated by PD-10 fractions was >98% and the
molecular weight of F(ab0)2 was 98.35 kDa. The average numbers of pSCN-Bn-DOTA che-
lates per antibody fragment were 5.03 ± 1.5 and the optimum conjugation reactions was
performed at molar ratio 20:1 (chelator to antibody). The stability test of the radio-
immunoconjugate in the human serum albumin (HSA) at 37 C showed the radiochemical
purity was 91.96 ± 0.26% after 96 h storage. This indicated that the radioimmunoconjugate
is relatively stable when applied to the human body's physiological condition.
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Radioimmunotherapy using monoclonal antibodies (mAb)
has been widely studied for the diagnosis and treatment of
cancer today (Huang, Pourgholami, & Allen, 2012; Rasaneh,
Rajabi, Babaei, Johari-Daha, & Salouti, 2009; Stein et al.,
2001). In radioimmunotherapy, a radioisotope is coupled to a
monoclonal antibody (mAb) to form a tumor-specific target
agent. Trastuzumab (Herceptin) is a humanized IgG1 mono-
clonal antibody that has recently been used in immuno-
therapy by directed against the extracellular domain of the
human epidermal growth factor receptor 2 (HER2) and used in
patients whose tumors overexpress this receptors (Garrett
et al., 2007; Hatem et al., 2011). Several previous studies re-
ported that these receptor (HER-2) was overexpressed in some
cancer cells such as breast cancer (McKeage & Perry, 2002;
Nuti et al., 2011).
The use of trastuzumab directly to the cancer therapy still
has many weaknesses, especially due to the relatively large
size (approximately 150 kDa), thus it is less effective in
reaching the target cells (low pharmacokinetics) and the lack
of penetration of the tumor cell (poor tumor penetration)
(Huang et al., 2012; Khawli, Biela, Hu, & Epstein, 2002; Tang
et al., 2005; Yokota, Milenic, Whitlow, & Schlom, 1992).
Moreover in the form of radioimmunoconjugate, trastuzumab
is not ideal for radioimmunotherapy, because it is slowly
eliminated from the blood and normal tissues yielding low
tumor blood (T/B) and tumor/normal tissue (T/NT) ratios
(Ramli, Humani, Rustendi, Subur, & Karyadi, 2009; Scollard,
Chan, Holloway, & Reilly, 2011). The solution to these myriad
obstacles is to reduce the size of intact antibodies to smaller
forms or fragments by enzymatic hydrolysis or genetic engi-
neering. Enzymatic fragmentation of antibody is much easier
to accomplish because it does not require complicated steps
and the cost is relatively cheap (Wong et al., 2011). The biva-
lent F(ab0)2 fragment can be produced by pepsin hydrolysis
whichwill generate Fc fragments and F(ab0)2 fragment (Khawli
et al., 2002). The removal of the Fc segment could reduce the
non-specific binding of the mAb via the Fc receptors found on
normal cells.
In order to overcome some of the limitations of antibody-
based imaging and therapeutic agent, we designed a radio-
pharmaceutical agents based on trastuzumab F(ab0)2 fragment
by conjugating it with radionuclides Lutetium 177. 177Lu was
selected as a potential radionuclide considered with the abil-
ity of emitting b and g particle. It was expected to serve as an
agent to prevent cancer cell proliferation through energy
transfer from the emission of b particles that are able to
destroy cancer cells (Oriuchi, Higuchi, Hanaoka, Iida, & Endo,
2005). Meanwhile, the emission of gamma particles is
commonly used for cell imaging to determine the shape and
size of the breast cancer cells (Rasaneh et al., 2009). Moreover,
177Lu can be produced in the reactor at large scale, with low
price and high specific activity (Rasaneh et al., 2009; Zoller,
Eisenhut, Haberkorn, & Mier, 2009).
177Lu decays with a half life of 6.73 d by emission of b-par-
ticles with maximum energies of 497 keV (78.6%), 384 keV
(9.1%), and 176 keV (12.2%) to stable 177Hf (Firestone, 1996). Theemission of suitable energy g photons of 113 keV (6.4%) and
208 keV (11%) (Firestone, 1996) with relatively low abundances
provides the opportunity to carry out simultaneous scinti-
graphic studies, which helps to monitor the proper in vivo
localization of the injected radiopharmaceutical as well as to
perform dosimetric evaluations. The low energy of its b and g
particles was suitable for imaging and therapeutic purposes
because of low tissue penetration range which might make it
more effective for small tumors (Oriuchi et al., 2005).
The stability test of 177Lu-DOTA trastuzumab which was
incubated in human serum showed that it was quite stable
with consistent radiochemical purity level above 99% for up to
120 h (Ramli et al., 2009). Biodistribution test of 177Lu-DOTA
trastuzumab in normal mice suggested that the radioactivity
in the blood decreased from 11.47 ± 0.28 to 4.57 ± 1.24% after
72 h post injection. However, the nature of radioactivity in the
liver was found relatively more stable 2.70 ± 0.80% two hours
after injection and 2.03 ± 0.87% 72 h post-injection (Ramli
et al., 2009). This condition showed that 177Lu-DOTA-trastu-
zumab clearance rate in the liver was very slow (long bio-
distribution). This phenomenon was probably due to the size
of antibodies which was not ideal so it did not directly go to
the target cell.
Our aim in this study was to formulate a radio-
immunoconjugate 177Lu-DOTA-F(ab0)2-trastuzumab fragment
starting with fragmentation of trastuzumab IgGmolecules into
(Fab0)2 followed by conjugation fragmentswith pSCN-Bn-DOTA
and radiolabelingwith 177Lu. Preparationof antibody fragments
such as F(ab0)2 is expected to be better for tumor imaging rather
than intact IgG because they are eliminated quickly from the
blood and normal tissues (except kidneys). They can achieve
high T/B and T/NT ratios and are not sequestered by the liver
(because of the absence of the Fc domain) (Tang et al., 2005;
Wong et al., 2011). To overcome the stability of the radio-
immunoconjugates produced, stability test performed by stor-
ing of radioimmunoconjugate at room temperature and in
humanserumalbumin (HSA) at 37 C.The result of this stability
test was expected to serve as an initial step in the development
of HER2 positive breast cancer theranostic agents.2. Materials & methods
2.1. Materials
Trastuzumab (Herceptin) was purchased from HoffmanneLa
Roche (Mississauga, Ontario). F(ab0)2 fragments were pro-
duced by digestion of trastuzumab IgG using pepsin (P6887
SigmaeAldrich), the conjugation of F(ab0)2 trastuzumab was
carried out by S-2-(4-isothiocyanabenzyl)-1,4,7,10-tetraazacyclo-
dodecane tetraacetic acid (pSCN-Bn-DOTA) as metal chelator
agent (Macrocyclics). 177LuCl3 was prepared by irradiation of
0.5e1.0 mg 176Lu (176Lu2O3, enrichment 60.60%) in RSG-GAS
(Multipurpose Reactor e GA Siwabessy BATAN) (neutron
flux: 1.26  1014 n cm2 s1) for 4e10 days. Irradiated targets
were dissolved in 6 M HCl and reconstituted with 3 mL of HCl
0.5 M resulting in radioactive concentration ±398.667 mCi/
mL.
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Prior to fragmentation of intact antibody of trastuzumab,
±10 mg/mL trastuzumab (HerceptinTM) was dissolved in 0.9%
saline solution then dialyzed in acetate buffer (0.02 M pH 4.5)
at 4 C for 72 h with three buffer changes. The final concen-
tration of dialyzed trastuzumab was measured by Bradford
method using UV-Vis Spectrophotometer (Shimadzu). A
number of 2.5 mg pepsin (3200 U/mg) was added to a solution
of 10mL dialyzed trastuzumabwith a ratio of pepsin/antibody
1:4. Themixturewas subsequently incubated in Thermomixer
(Eppendorf) in 350 rpm at 37 C for 18 h (Hermanto, Haryuni,
Ramli, Mutalib, & Hudiyono, 2012). Incubation of mixture
was quenched by the addition of 10mM triseHCl buffer pH 8.0
to the aliquot. The mixture is stored at 4 C for subsequent
fractionation by Sephadex G-25 column (PD-10) (GE Health-
Care). Fragmented protein profile was eluted in sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) (Bio-Rad).2.3. Separation and purification of F(ab0)2 trastuzumab
Before separation, PD-10 column was previously blocked with
1 mL of 10% BSA. After the column was ready for used, the
mixture was eluted in phosphate buffer saline (PBS 0.01 M pH
7.4). Unattached fraction was collected as a F(ab0)2 fragment.
Purity level of F(ab0)2 fragment was evaluated by SEC-HPLC
(Shimadzu) (Hermanto et al., 2012), and the molecular
weight of F(ab0)2 fragment was determined by LCMS (Waters).2.4. Conjugation of DOTA-F(ab0)2 trastuzumab
F(ab0)2 fragment of trastuzumab was conjugated with pSCN-
Bn-DOTA by incubating the antibody fragment (±1 mg) with
5, 10, 20, 30 and 50-fold molar ratio of the bifunctional
chelating agents (pSCN-Bn-DOTA) in ammonium acetate
buffer (0.25M pH 8.5) for 24 h at 4 C. The conjugateswere then
separated from non reacted chelates using Slide A-Lyzer
dialysis cassette 20 k MWCO (Thermo Scientific Pierce) in
ammoniumacetate buffer (0.25M pH 8.5) with 2 g of Chelex for
48 h with 3 times buffer replacement (Ramli et al., 2009; Vera
et al., 2012).2.5. Determining the average number of chelates per
antibody fragment
The average number of DOTA molecules bound to Fab2 frag-
ment was determined by analyzing the increase in molecular
weight of the DOTA-Fab2 conjugates generated by using SEC-
HPLC (Shimadzu) with Bio-SEC Suite S250 7.5  300 mm col-
umn (Waters). The peak produced was compared with a peak
of pure Fab2 in PBS eluent (0.01 M pH 7.4). The optimization of
conjugation efficiency was determined by calculating the
radiolabeling yields of each conjugates on instant thin layer
chromatography silica gel (ITLC-SG) with varying molar ratios
(Vera et al., 2012).2.6. Radiolabeling DOTA-F(ab)2 trastuzumab
177LuCl3 (2.5e3.1 mCi in 10e20 ml of 0.1 M HCl) was added to
200 ml of NH4OAc buffer (0.25 M, pH:7.5) containing 200e300 mg
of the DOTA-trastuzumab conjugate. The final mixture had a
specific activity (4e5 mCi mg1). The pH of complex solution
was then adjusted to 5.5 with HCl 1 M followed by incubating
the mixture in thermomixer 450 rpm at 42 C for 1 h. The la-
beling was quenched with 5 mM EDTA aliquot and incubated
for a further 15 min. The 177Lu-DOTA-F(ab0)2 trastuzumab
complex was purified by gel filtration on a Sephadex-G25
column (Amersham Pharmacia Biotech) and eluted with
phosphate buffered saline (PBS) supplemented with 0.5%
bovine serum albumin (BSA) (Ramli et al., 2009).2.7. Radiochemical purity evaluation
The radiochemical purity of the radioimmunoconjugate was
analyzed by ITLC-SG. Briefly, 2 ml of themixturewas applied to
strips ofWhatman paper (no. 1, 1 10.5 cm) at 1.5 cm from the
bottom. The solvent (0.9% saline, pH 7) was allowed to rise to
10 cm from the bottomof the strips. The stripswere then dried
and radiochemical purity was calculated by TLC Scanner
(Bioscan B-AR-2000 radio-TLC Imaging Scanner).2.8. The stability test of radioimmunoconjugate in PBS
buffer and human serum albumin (HSA)
Sample of 1 mL of human serum albumin and phosphate
buffer was prepared. An aliquot of 200 ml of the
177LueDOTAeF(ab0)2 trastuzumab complex was added to each
sample, and the sampleswere incubated at 37 C. The samples
were analyzed by ITLC after 1, 24, 48, and 72 h of incubation.
Prior to analysis, 5 mL EDTA 0.05 Mwas added into the samples
and the mixture was incubated for 15 min. The same proce-
dure was repeated, incubating the complex in phosphate
buffer samples (pH 7.4) at room temperature. Each of experi-
ments was repeated twice and radiochemical purity of sam-
pleswas calculated by g-counter (Rahmania, Mutalib, Ramli,&
Levita, 2015).3. Result and discussion
In this study, we report for the first time, the formulation,
characterization and stability test of radioimmunoconjugate
of F(ab0)2 fragments of the humanized HER2mAb trastuzumab
(Herceptin) labeled with 177Lu.3.1. Preparation of F(ab)2 fragments of trastuzumab
(Herceptin)
In our preliminary study, the conditions for preparation of
trastuzumab F(ab)2 fragment were optimized by varying the
pepsin/antibody ratio (1:2, 1:4 and 1:8) and optimizing the in-
cubation time (0, 6, 12, 18, 24 and 30 h) (Walker, 2002). Incu-
bation of trastuzumab IgG with a pepsin/antibody ratio 1:4
(wt./wt.) in an acetate buffer (0.02 M, pH 4.5) generated the
maximum yield of F(ab0)2. The optimizing time of enzymatic
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of trastuzumab at 18 h (Hermanto et al., 2012).
3.2. Purification of F(ab0)2 trastuzumab
To confirm the molecular weight of F(ab0)2 in quantitative
analysis, the pure F(ab0)2 fragments were needed in large
quantities. Scale up purification of F(ab0)2 fragments was done
by using PD-10 column in phosphate buffer eluent (0.01 M pH
7.4). Fraction of F(ab0)2 results was collected and the puritywas
examined. Size-exclusion HPLC confirmed the high purity of
trastuzumab F(ab0)2 fragments, revealing onemajor peak with
tR ¼ 11.92 min (~98%) and two much smaller peaks (fFc) with
tR ¼ 14.4 min and 17.72 min, while the single peak of trastu-
zumab IgG appeared at tR ¼ 11.27 min (Fig. 1).
The absence of a peak with tR ¼ 11.27 min in fractionation
results indicated that no intact trastuzumab IgG remained.Fig. 1 e Size exclusion HPLC analysis of trastuzumab (Herceptin
represents absorbance at 280 nm on a BioSep SEC-3 Agilent col
rate of 0.5 mL/min. The retention time (tR) of trastuzumab IgG w
The purity of trastuzumab F(ab′)2 was 98%.
Fig. 2 e The mass spectrum of trastuzumaThe smaller peak which was revealed later indicated the fFc
fragments that had been further hydrolyzed into lower mo-
lecular weight (Hermanto et al., 2012). The trastuzumab F(ab0)2
fragments from purification were further dissolved in
ammonium format buffer (50 mM pH 6.5). Their molecular
weight was determined by using LCMS/ESI-MS. The MS anal-
ysis showed that F(ab0)2 fragment had a molecular weight of
98.35 kD (Fig. 2).3.3. Determination of molecular weight of F(ab0)2
fragment
The molecular weight of F(ab0)2 fragment from MS analysis
was compared to in silico molecular weight prediction by
recalculating the total amino acids after pepsin digest of the
whole polypeptide. The amino acid sequences of the light) IgG (orange) and trastuzumab F(ab′)2 (blue). Signal
umn eluted with 0.01 M phosphate buffer (pH 7.4) at a flow
as 11.27 min and the tR of trastuzumab Fab was 11.92 min.
b F(ab′)2 fragment from LCMS/ESI-MS.
Fig. 3 e The amino acid sequences of one side of
trastuzumab IgG and the hydrolyzed site of
pepsin (sequences obtained from www.drugbank.ca/
drugs/DB00072).
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hidrolized by pepsin were shown in Fig. 3.
The total amino acids of F(ab0)2 chain from in silico predic-
tion contain 458 residues, with composed 214 residues (light
chain) and 244 residues (heavy chain), so that the molecular
weight predicted was 49287.22 Da, or 49.29 kD. Because the
molecule F(ab0)2 fragment composed of two pairs of F(ab0), the
molecular weight calculated theoretically was double of
49.29 kDa, or approximately 98.56 kDa. This suggests that the
molecularweight frominsilicocalculationwasnotsignificantly
different with the experimental measurement (98.35 kDa).Fig. 4 e Scheme of conjugation reaction between p-S3.4. Conjugation and determination the average number
of chelates per antibody fragment
The next step of radioimmunoconjugate synthesis was
conjugating of pSCN-Bn-DOTA to F(ab0)2 fragment and radio-
labeling the conjugate with 177Lu. The proposed scheme for
conjugation reaction between pSCN-Bn-DOTA with F(ab0)2
trastuzumab is given in Fig. 4.
Conjugation of F(ab0)2 and pSCN-Bn-DOTA was conducted
at 5, 10, 20, 30 and 50-fold molar ratio of the bifunctional
chelating agents/antibody in ammonium acetate buffer. The
yield of conjugation results in various molar ratios are shown
in Fig. 5.
The most optimum yield of % radiochemical purity of
conjugate obtained in 20-fold molar ratio with the radio-
chemical purity of complex was 84.73%. To determine the
average number of chelates per antibody fragment, the con-
jugate fragments characterized by using size exclusion HPLC
at 280 nm. At the same time the chromatogram obtained from
trastuzumab F(ab0)2 fragments compared to the DOTA-F(ab0)2
conjugate with the same condition. The retention time (tR) of
DOTA-F(ab0)2 trastuzumab obtained from HPLC was shorter
(11.840 min) than tR F(ab0)2 fragment (11.917 min) (Fig. 6). The
difference of these retention time indicated that there was an
increase in the conjugate molecular weight. On the average,
approximately 5.03 ± 1.5 pSCN-DOTA analogues were conju-
gated to trastuzumab and those average numbers achieved byCN-Bn-DOTA, F(ab′)2 trastuzumab and
177LuCl3.
Fig. 5 e The mole ratio of F(ab′)2: pSCN-DOTA and the %
radiochemical purity of radioimmunoconjugate.
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molar ratio. When it is compared with intact trastuzumab
conjugation (Rasaneh et al., 2009) it was 2.1e2.7 DOTA ana-
logues were conjugated to trastuzumab and the conjugation
reactions were performed at 20:1 M ratio for NHS-DOTA to
trastuzumab. Increasing in the average number of complex
DOTA-F(ab0)2 probably because of the F(ab0)2 structure was
more flexible than the intact antibody.Fig. 6 e Chromatogram of DOTA-F(ab′)2 trastuzumab (blue) with
(orange) with tR ¼ 11.917 min.
Fig. 7 e Radiochromatogram of 177Lu-EDTA (A) and radioimmun
ITLC-SG.3.5. Radiolabeling of DOTA-F(ab)2 trastuzumab
In order to monitor the formation of 177Lu-DOTA-F(ab0)2 tras-
tuzumab, the sample was analyzed by instant thin layer
chromatography (ITLC-SG) developed in saline solution (0.9%)
as a mobile phase (Ramli et al., 2009). This technique was
expected to be able to separate free 177Lu (chelating in EDTA)
from complex of 177Lu-DOTA-trastuzumab. The radiolabeling
results were shown in Fig. 7. Labeling percentage was ob-
tained by comparing the counts under peak of 177Lu-DOTA-
F(ab0)2 trastuzumab to the total counts.
It can be derived that the free 177Lu (as Lu-EDTA)was eluted
in 100 mm while 177Lu-DOTA-F(ab0)2 trastuzumab was detec-
ted in 23mm.Meanwhile that 177Lu-DOTA-trastuzumab could
be separated from the free 177Lu. Based on the radiolabeling
DOTA-F(ab0)2 that was carried out for 1 h, it can be identified
that the radiochemical purity of 177Lu-DOTA-F(ab0)2 trastuzu-
mab still relatively low. Due to its low purity, it is not good
enough to radioimmunoconjugate to be used as radio-
immunotherapy agents. Therefore the purification of radio-
immunoconjugate was very important, due to the purpose of
stability test of these molecules for theranostic agent.tR ¼ 11.840 min compared to trastuzumab F(ab′)2 fragment
oconjugate 177Lu-pSCN-DOTA-F(ab′)2 trastuzumab (B) from
Fig. 8 e Specific radioactivity of radioimmunoconjugate
177Lu-DOTA-F(ab′)2 trastuzumab from purification in PD-10
column (absorbance of complex measured in 280 nm).
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out by PD-10 desalting column to obtain radiochemical purity
of >95% aswell as requirement for goodmolecular theranostic
agent. Each fraction was counted for its specific radioactivity
and calculation result plotted on Fig. 8. The first peak (fraction
12) at chromatogram was predicted to be 177Lu-DOTA-F(ab0)2
trastuzumab molecule and the second peak (fraction 23) was
177Lu-EDTA.
Both peaks (fraction 12 and 23) were analyzed using TLC
system to determine the radiochemical purity. After purifi-
cation, the radiochemical purity increased to 98.45%. The
highest activity in the first purification of fragments showed
very good radiochemical purity (>98%). As can be seen, the
specific activity of the complex was 870e1220 mCi/mg at
phosphate buffer pH of 7.4.3.6. The stability test of the complex in PBS buffer and
human serum albumin (HSA)
Molecular theranostic agent should be stable, intact and not
degraded during storage. Stability test of the complex 177Lu-
DOTA-trastuzumab was carried out in storage at room tem-
perature in PBS buffer and at 37 C in human serum albumin
(HSA). The incubation timewas set on 1, 24, 48, and 72 h. Table
1 showed the result of stability test of the complex 177Lu-
DOTA-F(ab0)2-trastuzumab.
It can be seen the radioimmunoconjugate complex in HSA
were relatively stable after 96 h incubation, with radiochem-
ical purity 91.96 ± 0.26% respectively, but slightly different
from the complex stored in PBS buffer at room temperature
while radiochemical purity was only 76.32 ± 0.23 after 96 h of
storage. The stability of radioimmunoconjugate in HSATable 1 e The stability test result of
radioimmunoconjugate 177Lu-DOTA-F(ab′)2 trastuzumab.
Storage time Radiochemical purity (%)
HSA 37 C PBS (room temperature)
1 h 98.06 ± 0.36 96.89 ± 0.63
24 h 94.80 ± 0.61 95.51 ± 0.47
48 h 93.04 ± 0.73 90.97 ± 2.16
72 h 92.85 ± 0.77 87.37 ± 1.89
96 h 91.96 ± 0.26 76.32 ± 0.23probably caused by protein-ligand interactions was stabilized
by another protein environment around it. This results was
not quietly different to that reported by Scollard et al. (2011)
where specifications of radioimmunoconjugate 111In-DTPA
trastuzumab Fab was stable for 24 h stored at 4 C with the
mean radiochemical purity was 90.3 ± 2.5%.
Prior to application of pre-clinical trials, the radio-
immunoconjugate derived from this study should be tested
for its immunoreactivity with HER2 on SKBR-3 human breast
cancer cells by radioligand binding assay follow up by bio-
distribution study to monitor the proper of the injected
radiopharmaceutical in vivo as well as to perform dosimetric
evaluations for the patients and compared with the whole
trastuzumab IgG antibody.4. Conclusion
We concluded that radioimmunoconjugate 177Lu-DOTA-
F(ab0)2 trastuzumab can be successfully produced by pepsin
digestion of trastuzumab IgG and radiolabeled with 177Lu
through conjugation of pSCN-bn-DOTA as metal chelators.
The average number of pSCN-Bn-DOTA chelates per antibody
fragments was 5.03 ± 1.5 and the optimum conjugation re-
actions were performed at molar ratio 20:1 (chelator to anti-
body) with radiochemical purity >98% after purification. The
stability test of the radioimmunoconjugate complex in HSA at
37 C showed that the radiochemical purity was stable at
91.96 ± 0.26% after 96 h of storage.Acknowledgements
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